A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Vixotrigine (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Biogen
- 09 May 2018 Status changed from not yet recruiting to recruiting.
- 24 Jan 2018 Planned End Date changed from 1 Jul 2019 to 27 Aug 2020.
- 24 Jan 2018 Planned primary completion date changed from 1 Jul 2019 to 27 Aug 2020.